iExosomes 治疗携带 KRAS G12D 突变的转移性胰腺癌
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
这是一项 I/II 期注册临床试验,评估间充质干细胞治疗胰腺癌的安全性、可行性及初步疗效。当前状态:招募中。计划入组 28 例。试验地点:美国 · 休斯顿(共 1 个中心)。登记号:NCT03608631。
ALL SOURCES
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
这是一项 I/II 期注册临床试验,评估间充质干细胞治疗胰腺癌的安全性、可行性及初步疗效。当前状态:招募中。计划入组 28 例。试验地点:美国 · 休斯顿(共 1 个中心)。登记号:NCT03608631。
Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance
越来越多的证据表明,肿瘤相关成纤维细胞(CAF)的巨自噬/自噬在肿瘤发生发展中至关重要,并可能成为胰腺导管腺癌(PDAC)的治疗靶点。
Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features
MEKi+STAT3i联合治疗可减轻基质炎症,并富集具有间充质干细胞样特性的CAF表型,从而克服PDAC中的免疫治疗耐药。
Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy.
这些研究结果表明,MSC 来源的外泌体能够高效地包裹并递送 PTX,从而增强其抗肿瘤疗效。
Exosome-mediated triple drug delivery enhances apoptosis in pancreatic cancer cells.
经 iEXO-DG-ICG 处理后,肿瘤细胞中 galectin-9 的蛋白表达下降了 79%,CD8⁺ T 细胞和 IFN-γ⁺CD8⁺ T 细胞比例升高,而调节性 T 细胞比例下降。
Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer.
胰腺癌被认为是各种实体瘤中最致命的,五年生存率为13 %。
Targeting Reprogrammed Cancer-Associated Fibroblasts with Engineered Mesenchymal Stem Cell Extracellular Vesicles for Pancreatic Cancer Treatment.
背景:作为最具侵袭性和致死性的癌症之一,胰腺癌与影响癌症发生和进展的癌症相关成纤维细胞(CAFs)高度相关。
Exosomes and pancreatic diseases: mechanisms, applications, and challenges.
外泌体是多种细胞类型分泌的纳米级细胞外囊泡,已成为胰腺疾病中细胞间通讯的关键介质。
Mesenchymal stem cell-derived exosomes: Regulators of progression and suppression in pancreatic cancer (Review).
胰腺癌是一种预后不良的消化道恶性肿瘤。
Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review.
胰腺癌具有高转移潜能和低生存率,其原因在于治疗药物无法到达处于致密促结缔组织增生微环境中的癌细胞。
MEMBER ACCOUNT
登录成功会直接打开下一页。